Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 6, 2002, Pages 1199-1202

  Barak, Yoram ^a,b   Shamir, Eyal ^a,b   Zemishlani, Hanna ^a,b   Mirecki, Ilona ^a,b   Toren, Paz ^b,c   Weizman, Ronit ^b,c  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

Author keywords

Elderly; Olanzapine; Schizophrenia; Switching

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; MALE; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0036776230     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00322-0     Document Type: Article

References (14)

1. Altamura A.C., Curreli R. Antipsychotics in the elderly: the use of "typical" vs. "atypical" compounds. Brunello N., Langer S.Z., Racagni G. Mental Disorders in the Elderly: New Therapeutic Approaches. 1998;123-138 Karger, Basel.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. fourth ed. 1994;APA Press, Washington, DC. Chapter 10.
3. Chan Y., Pariser S.F., Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy. 19:1999;811-822.
4. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. 1976;US Department of Health Education, and Welfare, Washington, DC.
5. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
6. Kumar V., Brecher M. Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. J. Clin. Psychiatry. 60(Suppl. 13):1999;5-9.
7. Leucht A., Pitschel-Waltz G., Abraham D. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35:1999;51-68.
8. Madhusoodanan S., Suresh P., Brenner R., Pillai R. Experience with the atypical antipsychotics - risperidone and olanzapine in the elderly. Ann. Clin. Psychiatry. 11:1999;113-118.
9. Massand P.S. Weight gain associated with atypical antipsychotics. J. Psychotic Disord. 2:1998;4-6.
10. Massand P.S., Berry S.L. Switching antipsychotic therapies. Ann. Pharmacother. 34:2000;200-207.
11. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry. 58(Suppl. 10):1997;45-49.
12. Rabinowitz J., Lichtenberg P., Kaplan Z. Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr. Res. 46:2000;91-96.
13. Steffens D.C., Krishnan R.R. Metabolism, bioavailability, and drug interactions. Clin. Geriatr. Med. 14:1998;17-31.
14. Thornley B., Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ [Br. Med. J.]. 317:1998;1181-1184.